Nottingham, United Kingdom

Dipak Gordhan

This inventor holds 1 USPTO granted patent. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dipak Gordhan. Retrieved from https://idiyas.com/inventor/dipak-gordhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dipak Gordhan and His Pharmaceutical Patent

Introduction

Dipak Gordhan is an inventor associated with Nottingham, Great Britain. His patent work concerns pharmaceutical compositions involving pralsetinib, a selective RET inhibitor. The available information identifies 1 patent associated with him.

Latest Patents

“Pralsetinib Pharmaceutical Compositions” describes an amorphous solid dispersion containing pralsetinib, or a pharmaceutically acceptable salt of it, together with a hydrophilic polymer and an effervescent couple. The disclosure also covers crystalline forms of pralsetinib and pralsetinib hydrochloride salt, pharmaceutical compositions containing those forms, and methods for using the compositions to treat various disorders.

Career Highlights

Gordhan is associated with Rigel Pharmaceuticals, Incorporated. His identified patent reflects work on pharmaceutical formulations and crystalline forms intended for therapeutic use.

Collaborations

The listed coworkers associated with Gordhan include Joshua Waetzig and Shellie Rigby-Singleton.

Conclusion

Dipak Gordhan’s identified patent focuses on pralsetinib formulations and crystalline forms, highlighting his contribution to pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…